Compare INGN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | GANX |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.8M | 159.2M |
| IPO Year | 2014 | 2021 |
| Metric | INGN | GANX |
|---|---|---|
| Price | $7.20 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $11.00 | $8.00 |
| AVG Volume (30 Days) | 156.7K | ★ 2.2M |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $347,028,000.00 | N/A |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $8.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.68 | N/A |
| 52 Week Low | $5.70 | $1.41 |
| 52 Week High | $12.91 | $4.34 |
| Indicator | INGN | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 38.50 |
| Support Level | $6.53 | $2.30 |
| Resistance Level | $7.46 | $3.29 |
| Average True Range (ATR) | 0.18 | 0.48 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 72.04 | 19.33 |
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.